M.D. ANDERSON WILL COMPARE KYTRIL AND ZOFRAN IN HEAD-TO-HEAD TRIAL
M.D. ANDERSON WILL COMPARE KYTRIL AND ZOFRAN IN HEAD-TO-HEAD TRIAL of the two anti-emetics expected to begin this summer. The M.D. Anderson Cancer Center, one of the largest purchasers of Glaxo's Zofran (ondansetron), added SmithKline Beecham's Kytril (granisetron) to its formulary in mid-April "for a period of time" to evaluate Kytril's effectiveness and monitor its use. SB introduced Kytril March 23.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth